Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus
Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial with SB414
Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has completed a transaction with KNOW Bio, LLC granting Novan exclusive worldwide rights for certain oncovirus applications of nitric oxide-based products. An oncovirus is a virus that causes cancer. The agreement allows Novan to expand its viral platform by exploring nitric oxide’s antiviral activity against neoplasias and carcinomas caused by high-risk human papillomavirus (HPV). Novan intends to focus HPV-related development on localized therapies to treat HPV-associated sexually transmitted infections, including pre-cancerous lesions of the cervix and anus.